Easom Eric
SEC CIK 1914503 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | CEO, Dir | 368.6K | $114.5K | $1.55M | 16 | 2022-03-29 | 2026-02-20 |
Most active insiders at ANTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Readnour Robin Shane | Dir | — | $316.7K |
| 2 | Eizen Joshua M | See Remarks | — | $52.9K |
| 3 | FitzPatrick Margaret M | Dir | $11.6K | — |
| 4 | Chanda Sanjay | Chief Development Off | — | $9,311 |
| 5 | Day Lucy | CFO | — | $8,862 |
| 6 | Prior Stephen David | Chief Strategy Off | — | $7,363 |
| 7 | Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| 8 | Trenor Cameron C. III | Chief Medical Off | — | — |
| 9 | Marks Gilbert Lynn | Dir | — | — |
| 10 | Martin Patricia A. | Dir | — | — |
| 12 | Easom Eric | CEO, Dir | — | — |
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-23 | 2026-02-20 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | A - Grant | $0.00 | +112.2K | 368.6K | +44% | $0 |
| 2025-06-03 | 2025-06-02 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | P - Purchase | $1.07 | +10.0K | 256.4K | +4% | +$10.7K | |
| D | 2025-02-28 | 2025-02-26 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | A - Grant | $0.00 | +145.2K | 246.4K | +144% | $0 |
| I | 2024-11-18 | 2024-11-18 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | P - Purchase | $1.00 | +50.0K | 1.07M | +5% | +$50.0K |
| A | 2024-03-29 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | A - Grant | $0.00 | +99.0K | 101.1K | +4,648% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | A - Grant | $0.00 | +99.0K | 101.1K | +4,648% | $0 |
| T | 2024-01-04 | 2024-01-02 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $20.09 | -2,777 | 2,130 | -57% | -$55.8K |
| I | 2023-05-15 | 2023-05-15 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | P - Purchase | $5.38 | +10.0K | 1.02M | +1.0% | +$53.8K |
| M | 2022-11-14 | 2022-11-10+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.32 | -4,436 | 4,907 | -47% | -$68.0K |
| M | 2022-11-09 | 2022-11-08+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.60 | -17.2K | 4,907 | -78% | -$267.8K |
| M | 2022-11-07 | 2022-11-03+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.86 | -35.2K | 6,943 | -84% | -$558.2K |
| M | 2022-11-02 | 2022-10-31+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.27 | -4,232 | 4,907 | -46% | -$64.6K |
| M | 2022-10-28 | 2022-10-27+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.19 | -2,607 | 6,590 | -28% | -$39.6K |
| M | 2022-10-26 | 2022-10-24+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $15.76 | -9,350 | 7,119 | -57% | -$147.4K |
| M | 2022-10-24 | 2022-10-20+ | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | S - Sale | $16.47 | -21.2K | 7,257 | -75% | -$349.9K |
| D | 2022-03-31 | 2022-03-29 | ANTX | AN2 Therapeutics, Inc. | Easom Eric | CEO, Dir | C - Cnv Deriv | — | +4,907 | 4,907 | New | — |
Purchase Sale Sale after option exercise All abbreviations